16,117 Shares in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Bought by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. bought a new stake in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 16,117 shares of the company’s stock, valued at approximately $655,000. Crossmark Global Holdings Inc. owned about 0.05% of Calliditas Therapeutics AB (publ) at the end of the most recent quarter.

Calliditas Therapeutics AB (publ) Price Performance

CALT stock opened at $40.00 on Friday. The company has a debt-to-equity ratio of 9.44, a quick ratio of 2.59 and a current ratio of 2.69. Calliditas Therapeutics AB has a 52-week low of $15.25 and a 52-week high of $43.00. The company has a market capitalization of $1.19 billion, a P/E ratio of -21.62 and a beta of 1.77. The company has a fifty day moving average price of $40.00 and a 200-day moving average price of $37.02.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.09. The firm had revenue of $52.36 million for the quarter, compared to analyst estimates of $42.89 million. Calliditas Therapeutics AB (publ) had a negative return on equity of 212.04% and a negative net margin of 30.18%. During the same quarter in the previous year, the company posted ($0.33) EPS. As a group, equities analysts expect that Calliditas Therapeutics AB will post -0.99 EPS for the current year.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.